Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Eli Lilly And Co (LLY) Price & Performance

Global X Artificial Intelligence & Technology ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global X Artificial Intelligence & Technology ETF vs Eli Lilly And Co — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.84, while Eli Lilly And Co trades at $1,222.8 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while Global X Artificial Intelligence & Technology ETF pays none. Which is the better fit depends on your goals.

AIQLLY
Sector
Sector/ThematicHealth
52-Week High
$70.14$1.24K
52-Week Low
$43.88$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ, the Global X Artificial Intelligence & Technology ETF, trades at $63.79, up 0.44% on the day, with a bullish technical signal driven by moving averages. The ETF has gained attention for outperforming broader indices, with recent news highlighting its 25% gain and positioning in the AI sector. Key resistance lies at $64, while support is near $63.

The outlook remains positive due to strong momentum in AI investments, but risks include sector volatility and high valuations. Analyst sentiment is generally optimistic, with the ETF seen as a diversified play on AI growth, though the absence of dividend income and fee considerations may weigh on long-term returns.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY